DOYLESTOWN, Dad.† June 20, 2022 /PRNewswire/ — assisTek, based in Doylestown, Pennsylvaniaannounced its latest collaboration with Philadelphia based Strados Labs. Strados Labs is known for their creation of advanced smart technology medical devices for respiratory diseases.
assisTek, has long been a leader in the eSource industry in various therapeutic areas, over 900+ global clinical trials and offering a range of services for the electronic collection of clinical data. Their technology offerings include eCOA, ePRO, eConsent, BYOD modules and an extensive reputation for their custom solutions supporting clinical research teams around the world. “We are very excited to announce this partnership and look forward to working with Strados to provide clinicians and patients with another way to collect new information during their trials. By seamlessly integrating into our current eDiary offering This paired technology will allow for better patient engagement and more efficient information collection, with the ultimate goal of improved data for cure and treatment of these conditions,” explains Richard GastineauCEO of assisTek.
Strados Labs is a medical technology company developing smart sensor platforms that use machine learning and proprietary algorithms to detect and predict compound conditions associated with severe, chronic respiratory disease to improve the lives of patients worldwide. “We are grateful and proud to strengthen our partnership with assisTek, who have been a leader in integrating technology and data collection into clinical trials for more than 20 years,” said Shane Krauss, director of business development, Strados Labs. “We look forward to partnering with their experienced and knowledgeable team in clinical trials by helping them scale their digital therapies using our clinically validated measurements for wheezing, coughing and other adventitious breath sounds, or CABS – something that no other wiped device can measure.” The company developed a unique platform for smart respiratory health sensors, RESP®. Strados recently received FDA Class II 510(k) approval for home use for its first product, RESP®, its second FDA approval in less than 18 months. RESP® also received a CE marking at the end of last year. The company is developing a robust pipeline algorithm to support and address other chronic diseases, as well as chronic disease management pathways. Strados will continue to focus on asthma, COPD and infectious respiratory diseases (COVID, RSV and more) – with plans to add heart failure and pediatrics later this year. The company is located in Philadelphia and is a private company.
Vice President, Commercial Affairs
SOURCE assisTek Inc